Loading...
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). The mechanisms by which SGLT2 inhibitors reduce such risk are likely to be independent of diabet...
Na minha lista:
| Udgivet i: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7722318/ https://ncbi.nlm.nih.gov/pubmed/33287812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01191-5 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|